Background
With expanding global antiretroviral therapy (ART) access, integrase strand transfer inhibitors (INSTIs) and protease inhibitors (PIs) are increasingly used in ART-experienced persons. Current data on the extent and impact of resistance in this population are limited yet needed to inform future ART options.
Methods
We reviewed clinical and genotyping records of ART-experienced persons in the Academic Model Providing Access to Healthcare (AMPATH), a large HIV treatment program in western Kenya. Persons were eligible if they underwent HIV-1 genotyping between 2021-2025 per national guidelines after 2 viral loads (VL) ≥1000 copies/mL despite enhanced adherence counselling on INSTI- and/or PI-based ART. Primary outcomes were intermediate- or high-level resistance by drug class assessed with Stanford Database tools, and viral suppression ≥6 months post-genotyping.
Results
Of 133 persons undergoing genotyping in this period, 104 (13 not found; 16 ineligible) were eligible (59% female, median age 35 years, median 14 years on ART). At genotyping, 83% were on PI-, 18% on INSTI-, and 1% on INSTI+PI-based regimens. Intermediate- or high-level resistance to any drug was detected in 90/104 (87%), including 33/96 (34%) to any PI and 3/96 (3%) to all PIs of those on or exposed to PIs; 75/104 (72%) to any NRTI and 20/104 (19%) to all NRTIs of those on or exposed to NRTIs; 77/97 (79%) to any NNRTI and 10/97 (10%) to all NNRTIs of those on or exposed to NNRTIs; and among 53 persons with available integrase sequences, 11/21 (52%) to any INSTI and 7/21 (33%) to all INSTIs of those on or exposed to INSTIs (major mutations G118R (n=7), T66IA (n=5), E138KA (n=7), R263K (n=4)). Post-genotyping, 17/104 (16%) remained on the same regimen, while 51 (48%) switched to INSTI-, 4 (4%) to PI-, 33 (31%) to PI+INSTI- and 1 (1%) to NNRTI-based ART. Among 88 persons with available VL ≥ 6 months post-genotyping (median 16 months), 57% had VL <40, 22% VL 40-199, 7% VL 200-1000, and 15% VL>1000 copies/mL. Of the latter (n=13), 11 were on INSTI-, 1 on PI- and 1 on NNRTI-based regimens, with 9 in care, 2 deaths and 2 lost to follow-up.
Conclusions
HIV drug resistance is common in ART-experienced Kenyans eligible for testing under national guidelines, including high-level resistance to INSTIs and PIs with high resistance barriers, and poor outcomes post-genotyping. Findings highlight the vulnerability of this advanced population in the INSTI era and the urgent need to address ongoing challenges to optimize treatment outcomes.